Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Investing.com - H.C. Wainwright has reiterated its Buy rating and $30.00 price target on BioCryst Pharmaceuticals (NASDAQ:BCRX), currently trading at $6.42, following the company’s move to acquire Astria Therapeutics. According to InvestingPro data, the stock is trading near its 52-week low of $6.00, suggesting potential value opportunity.
The acquisition represents a strategic expansion of BioCryst’s hereditary angioedema (HAE) portfolio, reinforcing an area where the company already holds commercial and scientific strength rather than pursuing new indications. The company’s strong commercial position is reflected in its impressive 45.85% revenue growth over the last twelve months.
The deal brings navenibart, a Phase 3 long-acting monoclonal antibody inhibitor of plasma kallikrein, into BioCryst’s pipeline, positioning the company to reach patients seeking less-frequent dosing or alternatives to daily oral therapy.
By adding a potentially twice-yearly injectable treatment to complement its established oral option, Orladeyo, BioCryst could capture both ends of the HAE prophylactic spectrum, offering patients more flexibility while strengthening its franchise in this therapeutic area.
The strategy highlights BioCryst’s intent to consolidate its leadership position in the HAE market and demonstrates confidence in the long-term profitability of this specialized therapeutic area, according to H.C. Wainwright.
In other recent news, BioCryst Pharmaceuticals has been the focus of several analyst updates and strategic moves. Notably, Cantor Fitzgerald raised its price target for BioCryst to $26, maintaining an Overweight rating, suggesting a stable outlook on the company’s long-term financials. TD Cowen resumed coverage with a Buy rating and a $30 price target, highlighting BioCryst’s acquisition of ATXS for around $700 million as a significant factor. This acquisition adds navenibart, a plasma kallikrein monoclonal antibody, to BioCryst’s offerings, enhancing its treatment options for hereditary angioedema (HAE).
Citizens also increased its price target to $27 from $17, citing the acquisition of navenibart as a key driver. RBC Capital raised its target to $15, maintaining an Outperform rating and emphasizing the strategic benefits of the ATXS acquisition, despite potential short-term dilution. Similarly, Jefferies increased its price target to $15 following BioCryst’s plan to acquire Astria Therapeutics for $13 per share, valuing the transaction at approximately $920 million. These developments reflect a general positive sentiment among analysts regarding BioCryst’s recent strategic acquisitions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.